Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells

被引:43
作者
Buss, I. [1 ]
Hamacher, A. [2 ]
Sarin, N. [1 ]
Kassack, M. U. [2 ]
Kalayda, G. V. [1 ]
机构
[1] Univ Bonn, Inst Pharm, Immenburg 4, D-53121 Bonn, Germany
[2] Univ Dusseldorf, Inst Pharmaceut & Med Chem, Univ Str 1, D-40225 Dusseldorf, Germany
关键词
CELLULAR ACCUMULATION; INFLUX TRANSPORTER; CAPILLARY-ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; PLATINUM DERIVATIVES; BINDING BEHAVIOR; HUMAN OVARIAN; CISPLATIN; EXPRESSION; CYTOTOXICITY;
D O I
10.1039/c7mt00334j
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxaliplatin is a routinely used drug in the treatment of colorectal cancer. However, development of resistance is a major hurdle of the chemotherapy success. Defects in cellular accumulation represent a frequently reported feature of cells with acquired resistance to platinum drugs. Nevertheless, the mechanisms of oxaliplatin uptake and their role in oxaliplatin resistance remain poorly elucidated. The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells. Co-incubation with copper(ii) sulfate, a CTR1 substrate, significantly decreased oxaliplatin accumulation but not cytotoxicity in both cell lines. Pre- as well as co-incubation with the OCT1 inhibitor atropine led to a significant reduction in oxaliplatin accumulation in sensitive but not in resistant cells. However, oxaliplatin cytotoxicity was also decreased in the presence of atropine in both cell lines. Cimetidine, an inhibitor of OCT2, induced a significant reduction in the cellular accumulation and potency of oxaliplatin in sensitive and resistant cells. An inhibitor of OCT3, decynium-22, had no influence on oxaliplatin accumulation and cytotoxicity in either cell line. No differences in the transporter expressions were observed between the cell lines, drug-treated or not, either at the mRNA or protein levels. A fluorescent oxaliplatin derivative CFDA-oxPt co-localized with CTR1, OCT1 and OCT2 in sensitive cells, but only with CTR1 and OCT2 in the resistant cell line. Our results suggest that oxaliplatin is transported into the cell by CTR1 in both cell lines. However, contribution of CTR1-mediated uptake to resistance seems unlikely. Uptake of oxaliplatin via OCT1 appears to take place in the sensitive but not in the resistant cell line underscoring the transporter relevance for oxaliplatin resistance. OCT2 is likely to be involved in the uptake of oxaliplatin to a similar extent in both cell lines suggesting no major contribution of this transporter to resistance. In contrast, OCT3 appears to be irrelevant for oxaliplatin transport into the cell and resistance.
引用
收藏
页码:414 / 425
页数:12
相关论文
共 43 条
[1]   Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1 [J].
Ahlin, Gustav ;
Karlsson, Johan ;
Pedersen, Jenny M. ;
Gustavsson, Lena ;
Larsson, Rolf ;
Matsson, Paer ;
Norinder, Ulf ;
Bergstroem, Christel A. S. ;
Artursson, Per .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (19) :5932-5942
[2]  
ALLEY MC, 1988, CANCER RES, V48, P589
[3]   Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) [J].
Burger, H. ;
Zoumaro-Djayoon, A. ;
Boersma, A. W. M. ;
Helleman, J. ;
Berns, E. M. J. J. ;
Mathijssen, R. H. J. ;
Loos, W. J. ;
Wiemer, E. A. C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (04) :898-908
[4]   Drug transporters of platinum-based anticancer agents and their clinical significance [J].
Burger, Herman ;
Loos, Walter J. ;
Eechoute, Karel ;
Verweij, Jaap ;
Mathijssen, Ron H. J. ;
Wiemer, Erik A. C. .
DRUG RESISTANCE UPDATES, 2011, 14 (01) :22-34
[5]  
Buss I, 2009, INT J CLIN PHARM TH, V47, P51
[6]   Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues [J].
Buss, Irina ;
Kalayda, Ganna V. ;
Lindauer, Andreas ;
Reithofer, Michael R. ;
Galanski, Markus ;
Keppler, Bernhard K. ;
Jaehde, Ulrich .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2012, 17 (05) :699-708
[7]   Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes? [J].
Buss, Irina ;
Garmann, Dirk ;
Galanski, Mathea S. ;
Weber, Guenther ;
Kalayda, Ganna V. ;
Keppler, Bernhard K. ;
Jaehde, Ulrich .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2011, 105 (05) :709-717
[8]   Cellular and molecular aspects of drugs of the future: oxaliplatin [J].
Di Francesco, AM ;
Ruggiero, A ;
Riccardi, R .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (11) :1914-1927
[9]  
Graham MA, 2000, CLIN CANCER RES, V6, P1205
[10]   The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy [J].
Hall, Matthew D. ;
Okabe, Mitsunorl ;
Shen, Ding-Wu ;
Liang, Xing-Jie ;
Gottesman, Michael M. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 :495-535